Get the Stockscreener App
1.72
4.24%
0.07
Pre-market:
1.73
0.01
+0.58%
Annovis Bio Inc stock is traded at $1.72, with a volume of 1.35M.
It is up +4.24% in the last 24 hours and down -16.50% over the past month.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
See More
Previous Close:
$1.65
Open:
$1.66
24h Volume:
1.35M
Relative Volume:
1.16
Market Cap:
$73.17M
Revenue:
-
Net Income/Loss:
$-40.92M
P/E Ratio:
-1.0019
EPS:
-1.7167
Net Cash Flow:
$-26.53M
1W Performance:
-1.71%
1M Performance:
-16.50%
6M Performance:
-52.22%
1Y Performance:
-20.74%
1-Day Range:
$1.65
$1.72
1-Week Range:
$1.645
$1.84
52-Week Range:
$1.5407
$5.50
Annovis Bio Inc Stock (ANVS) Company Profile
Name
Annovis Bio Inc
Sector
Industry
Phone
484-875-3192
Address
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
1.72 | 73.17M | 0 | -40.92M | -26.53M | -1.7167 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-10-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-25-24 | Upgrade | Maxim Group | Hold → Buy |
| Dec-29-23 | Initiated | Canaccord Genuity | Buy |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
Annovis Bio Inc Stock (ANVS) Latest News
Annovis Bio, Inc.(NYSE: ANVS) added to Russell Microcap Index - marketscreener.com
Annovis Bio | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Annovis Bio | DEFA14A: Others - Moomoo
ANVS Forecast — Price Target — Prediction for 2027 - TradingView
Annovis Bio Inc Actuals & Estimates (FWB:07X) - TradingView
07X Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Annovis Bio, Inc. – NYSE:ANVS - TradingView
Price to sales forward of Annovis Bio, Inc. – NYSE:ANVS - TradingView
Enterprise value to revenue forward of Annovis Bio, Inc. – NYSE:ANVS - TradingView
Annovis Bio Inc (ANVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Annovis Bio Shareholders Approve Governance and Compensation Changes - The Globe and Mail
Why Annovis’ buntanetap pill is drawing fresh attention in Alzheimer’s race - Ad-hoc-news.de
Annovis Bio Inc (ANVS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Annovis Bio shareholders approve all proposals at annual meeting By Investing.com - Investing.com Australia
Annovis Bio shareholders approve all proposals at annual meeting - Investing.com UK
Annovis Bio Inc (ANVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Annovis Bio Inc (ANVS) Institutional Confidence - TradingKey
Annovis Bio Inc (ANVS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Annovis Bio Inc (ANVS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Annovis Bio (NYSE: ANVS) holders expand equity plan and set biennial say-on-pay - Stock Titan
Annovis Bio Inc (ANVS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Annovis Bio Inc (ANVS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Annovis Bio Inc (ANVS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Press Release: Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants - 富途牛牛
Annovis Bio Inc Stock (US0360431013): Short Interest Climbs At End Of May - AD HOC NEWS
Annovis Bio Price, ANVS Price, Live Charts, and Marketcap - Coinbase
Annovis Regains NYSE Compliance Ahead of Listing Deadline - MyChesCo
Maxim Group Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Annovis Bio (ANVS) Faces Selling Pressure: Key Levels in Focus After 7.6% DeclineVolume Rate Change - thelegaladvocate.com
Annovis Bio regains NYSE listing compliance - MSN
Annovis Bio regains NYSE listing compliance By Investing.com - Investing.com Nigeria
Annovis Bio Regains NYSE Listing Compliance - The Manila Times
Annovis launches proposed public stock and warrant offering - MSN
Annovis Bio Analyst Ratings and Price Targets | NYSE:ANVS - Benzinga
Annovis Bio director Michael Hoffman buys $142,778 in shares By Investing.com - Investing.com Nigeria
Annovis Bio director Michael Hoffman buys $142,778 in shares - Investing.com UK
3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced - Moomoo
Annovis Bio (ANVS) Rebounds 5.39%, Tests Key Resistance After Broader Market Upward MomentumCorrective Wave - thelegaladvocate.com
Director Michael Hoffman adds 76,344 Annovis Bio (ANVS) shares in open-market buys - Stock Titan
Annovis Bio prices $15 million public offering at $1.90 - Investing.com UK
Annovis Bio Announces Dilutive Equity Offering for Trials - TipRanks
Annovis Bio Launches ~$15 Million Stock-and-Warrant Offering Underwritten by Canaccord Genuity - TradingView
Annovis Bio Inc Stock (ANVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):